Tags : Rekambys

Regulatory

ViiV Healthcare’s First Long-Acting Injectable Receive EC’s Approval for the

Shots: The approval is based on P-III ATLAS, FLAIR and ATLAS-2M studies assessing Vocabria (cabotegravir injection and tablets)  + Janssen’s Rekambys (rilpivirine inj.) or Edurant (rilpivirine tablets) in 1200+ patients for HIV-1 infection in adults who are virologically suppressed The first long-acting injectable can enable people living with HIV to reduce the days they receive […]Read More